BRIX1 and cancer: However, patients with BXDC2-negative/AR-positive muscle-invasive tumor had an insignificantly (p = 0.070) or significantly (p = 0.041) higher risk of disease progression (Figure 6D) or cancer-specific mortality (Figure 6E), respectively.